ARCHIVES

“Harm-Reduction” Products No Proven, IOM Report Says.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Advisors Approve Recompetition of Phase II Contracts

July 9, 1999

DCE Advisors OK Concepts for Registry, Grants In Breast Cancer

June 25, 1993

PSA Velocity Poor Predictor Of Prostate Cancer Occurrence

March 25, 2011

NCI To Offer Compromise On Including “Chop-Like Elements” In CCOP, Agrees Consortia “Appropriate”

May 14, 1982

MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies

December 28, 2012

After Aggressive Budgetary Trimming, At $33 Million NCI’s caBIG Remains Big

December 2, 2011